Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment for use in therapy

摘要

Subject matter of the present invention is an anti-adrenomedullin antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold wherein said antibody or said fragment or scaffold is a non-neutralizing antibody, antibody fragment or non-Ig scaffold, respectively. Subject matter of the present invention is also in anti-adrenomedullin antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in a treatment of a chronic or acute disease wherein said antibody or fragment or scaffold is an ADM stabilizing antibody or an adrenomedullin stabilizing antibody fragment or an ADM stabilizing non-Ig scaffold that enhances the t½ half retention time of adrenomedullin in serum, blood, plasma at least 10%, preferably at least, 50%, more preferably >50%, most preferably 100%, and/or wherein said anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold blocks the bioactivity of ADM to not more than 80%, or not more than 50%.

主权项

1. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and an anti-adrenomedullin (anti-ADM) antibody or an anti-ADM antibody fragment, which binds to a region of at least 4 amino acids (aa) within (aa 1-21) of mature human ADM (SEQ ID NO: 21), and not comprising an antibody or antibody fragment which binds to the C-terminal portion (aa 43-52) of mature human ADM (SEQ ID NO: 21).